Spignesi Robert G. Jr. 4

What Happened
Robert G. Spignesi Jr., President, CEO and Director of Rapid Micro Biosystems (RPID), was granted a total of 792,000 awards on Feb 11, 2026: 264,000 restricted stock units (RSUs) and 528,000 derivative awards (reported as an acquisition at $0). The grants were reported with a per-share acquisition price of $0, so the filing shows $0 immediate cash value for the awards.

Key Details

• Transaction date: February 11, 2026; Form 4 filed February 13, 2026 (two days later).
• Amounts: 264,000 RSUs (Award A) + 528,000 derivative/option-type award (Award A) = 792,000 total. Reported price per share: $0; reported cash value at grant: $0.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes:
  • F1 (264,000 RSUs): Vest in three annual installments — 33.4% on first anniversary (Feb 11, 2027) and 33.3% on each of the second and third anniversaries, subject to continued service.
  • F2 (528,000 derivative): Described as an option that vests in 48 substantially equal monthly installments, with the first installment vesting on March 11, 2026.
• Filing timeliness: Filed within two business days of the grant date (appears timely).

Context
These grants are awards of future equity (RSUs and an option-like derivative). RSUs and options do not represent immediate open-market purchases or sales — they vest over time and only convert to actual shares (or become exercisable) if the vesting conditions are met. Such awards are common compensation for executives; they can lead to future share issuance (dilution) if vested/settled, but do not indicate an immediate cash transaction or insider buying/selling activity.